A significant legal victory for intellectual property enforcement in the genomics sector has materialized as the U.S. District Court for the District of Delaware entered a final judgment against Guardant Health, Inc. (Nasdaq: GH). The court’s decision preserves a prior finding of willful patent infringement, resulting in a massive financial liability for Guardant Health. This ruling, which awards TwinStrand Biosciences and the University of Washington more than $245.2 million in damages, accrued royalties, and interest, underscores the high stakes of proprietary sequencing technologies. The judgment specifically addresses the infringement of two core patents underlying TwinStrand’s Duplex Sequencing® technology, impacting a substantial portion of Guardant Health's revenue stream and establishing a long-term royalty obligation.
$245.2 Million Award for Patent Infringement
The final judgment, entered on August 21, 2026, validates a November 2023 jury verdict that Guardant Health willfully infringed upon two patents: U.S. Patent Nos. 10,287,631 and 10,760,127. The total award of more than $245.2 million is composed of several distinct financial components. The court upheld the original $83.4 million damages award for infringement occurring through June 30, 2023. Additionally, the court granted $19.5 million in supplemental damages for sales between July 1, 2023, and February 5, 2024. A significant portion of the judgment, $119.4 million, represents accrued royalties calculated at a 6% rate for sales from February 5, 2024, through May 31, 2026. The remaining $22.9 million accounts for pre-judgment and post-judgment interest.
Crucially, the court did not merely award past damages; it established a continuing financial obligation. Guardant Health is ordered to pay a 6% royalty on sales of the 11 adjudicated products and services from June 1, 2026, until the patents expire on March 15, 2033. This royalty must be paid on a quarterly basis. To ensure compliance, the court mandated that Guardant Health provide TwinStrand and the University of Washington with a quarterly accounting of all U.S. sales for the covered products. This ruling follows the court's rejection of Guardant Health’s post-trial motions to overturn the verdict or secure a new trial.
Guardant Health Revenue and Product Exposure
The financial impact of this judgment is deeply integrated into Guardant Health’s core business model. During the relevant infringement period, the jury applied the 6% royalty rate to revenue attributed to the covered products and services, which represented approximately 90% of Guardant Health's total revenue. This high level of exposure suggests that the infringed technology is central to the company's commercial operations. The 11 specific products and services subject to the royalty include Guardant360 Lab Developed Test, Guardant360 CDx, GuardantOMNI, Guardant Reveal / LUNAR-1, Guardant360 Response, Guardant360 TissueNext, Guardant HEME, GuardantINFINITY / Sirius, Guardant LUNAR-2 / Shield, Guardant COMPANION, and Guardant EXPLORE.
The court's decision also serves as a critical validation of the intellectual property itself. By adopting TwinStrand’s proposed language on validity, the court upheld the asserted claims of both patents. While patent-related proceedings regarding these technologies remain ongoing before the U.S. Patent and Trademark Office and the Patent Trial and Appeal Board, neither patent has been invalidated. This legal outcome effectively blocks Guardant Health from utilizing the Duplex Sequencing® technology without paying the court-ordered 6% royalty, a mandate that will persist for several years. For Guardant Health, the dismissal or withdrawal of all its counterclaims prior to trial further isolates the company from legal recourse regarding these specific patent claims.
Key Takeaways
- The U.S. District Court for the District of Delaware awarded TwinStrand Biosciences and the University of Washington over $245.2 million in damages, royalties, and interest.
- Guardant Health is required to pay a 6% quarterly royalty on 11 specific products and services through the patent expiration date of March 15, 2033.
- The infringed technology, TwinStrand’s Duplex Sequencing®, was found to have been willfully infringed by Guardant Health, impacting products that represented roughly 90% of Guardant's revenue during the infringement period.
FinanceInsyte's Take
In our view, this judgment represents a watershed moment for intellectual property valuation within the precision genomics market. The fact that the infringing products accounted for approximately 90% of Guardant Health's revenue during the period in question highlights a profound strategic risk: the reliance on third-party IP that is later adjudicated as willfully infringed. This is not merely a legal setback; it is a structural financial burden that will compress margins for Guardant Health for the next seven years. For institutional investors, this case serves as a stark reminder to scrutinize the "IP moat" of biotech firms. The court's decision to uphold the 6% royalty rate on a massive revenue base suggests that the economic value of Duplex Sequencing® is substantial and that the cost of "building without a license" can be devastatingly high.
Questions & Answers
How does this judgment affect Guardant Health's long-term margin profile?
The judgment imposes a mandatory 6% royalty on sales of 11 key products and services through March 15, 2033. Because these products represented approximately 90% of Guardant Health's revenue during the infringement period, the company faces a sustained increase in cost of goods sold (COGS) that will likely compress operating margins for the duration of the royalty period.
What is the scope of the intellectual property protected by this ruling?
The ruling protects two specific patents—U.S. Patent Nos. 10,287,631 and 10,760,127—which underlie TwinStrand's Duplex Sequencing® technology. The court upheld the validity of the asserted claims in both patents, providing TwinStrand and the University of Washington with legal recourse against the unauthorized use of this technology in 11 specific Guardant Health products.
What was the total financial liability established by the court?
The total award exceeds $245.2 million. This figure includes $83.4 million in initial damages, $19.5 million in supplemental damages for sales between July 2023 and February 2024, $119.4 million in accrued royalties for sales through May 2026, and $22.9 million in interest.
Can Guardant Health challenge the validity of these patents further?
While the court has entered final judgment, the source notes that patent-related proceedings regarding these patents remain ongoing before the U.S. Patent and Trademark Office and the Patent Trial and Appeal Board. However, as of the announcement, neither patent has been invalidated.
Source: Businesswire
